Risk of #Nephrogenic Systemic #Fibrosis in Patients With Stage 4 or 5 Chronic #Kidney Disease Receiving a Group II Gad… https://t.co/opre9vGDqC
RT @kidney_boy: The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following…
RT @kidney_boy: The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following…
RT @kidney_boy: The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following…
RT @kidney_boy: The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following…
RT @kidney_boy: The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following…
The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following 4931 administrations of Group 2 GBCA to patients with CKD stage 4, 5 and ESRD, there were ZERO cases of NSF! https://t.co/DcDjS1jZAO
@kevinmooremd @DGlaucomflecken Also not an issue. Newer group II GBCA are safe in renal failure. https://t.co/YImocNFBr8
@nepherson Wow. Thank you so much this has bothered me for years. https://t.co/4SWrBoCk41
@CarolynParkMD @JenJordanPhD @MaheshAnandCh Couldn’t agree more. https://t.co/d17ybqVa9I upper 95 % ci of risk is <0.07 per study ; https://t.co/x7QluOwsV2 nephrologist advocating for no restrictions in ckd 4-5; scheduled HD after gd mri; only group in
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
Very important work - risk of nephrogenic systemic fibrosis after gadolinium administration is unlikely to outweigh the risks related to missing diagnoses! #CardioTwitter #WhyCMR
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
Pooled incidence of nephrogenic systemic sclerosis from contemporary Gd contrast agents (group 2; including gadobutrol) in this meta analysis of 4931 patients with CKD 4&5 is 0% (95%CI 0-0.07%) https://t.co/8aAWeucPOi
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @mgwfriedrich: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis | Chronic Kidney Disease | JAMA Internal Medicine | JAMA Network #whycmr
RT @kidney_boy: @PrathitKulkarni @TheRealDSrini And we might want to add theoretically to systemic sclerosis with newer gadolinium agents h…
RT @kidney_boy: @PrathitKulkarni @TheRealDSrini And we might want to add theoretically to systemic sclerosis with newer gadolinium agents h…
@PrathitKulkarni @TheRealDSrini And we might want to add theoretically to systemic sclerosis with newer gadolinium agents https://t.co/a0lcRsu3VT https://t.co/s2d8C5gYEc
@RebeccaEBerger @Gabby_Brauner27 Seems like in those with advanced CKD, NSF is extraordinarily rate https://t.co/KE23KkUkL7
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
@mpneph @askrenal @NephJC @CJASN @JASN_News @RadiologyACR I think of this article everytime this topic comes up. Not all patients with ESRD but 0 cases in 4931 administrations. https://t.co/rtLwcW0EQG
@experten88 @Longterms1 Titta gärna på den här när det gäller risker med grupp 2-gadolinium. https://t.co/9CQfaOQ1T7
Day 11 teaching service: Risk of nephrogenic systemic fibrosis #MedEd Risk is not the same for all gadolinium based contrast agents This study found risk of NSF from group II GBCA in stage 4 or 5 CKD is likely less than 0.07% https://t.co/miif5O0AHN
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
@drpaddymark will this affect the nephrologist's views on gadolinium based contrast agents? https://t.co/ETaRjUPwN4
Answer: 0-0.07% is the 95% confidence interval from a meta-analysis of 4,931 group II GBCM administrations to patients with eGFR<30. There were 0 cases of NSF. Source: Woolen et al. JAMA Int Med 2020 https://t.co/ZSqZKGFG5V
@kidney_boy, do you let your patients with advanced CKD use gadolinium, or is that still a hard no? Is this a practice we can feel more comfortable with if clinically indicated? Thanks! https://t.co/mIX0tUqtxa
RT @kdjhaveri: Newer data #KidneyWk NO cases of NSF on the newer agents https://t.co/3a2Lsmoia8 https://t.co/5XKTfDbouJ
Newer data #KidneyWk NO cases of NSF on the newer agents https://t.co/3a2Lsmoia8 https://t.co/5XKTfDbouJ
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
How did these papers get past me!?! Question is, whose shop is letting the gad slide for 4/5 CKD? https://t.co/LYTlnUpAeu https://t.co/liyL3ekx7W @Dr_Osms @hswapnil @ChristosArgyrop @BakrisGeorge @KhaledNashar4 @transplantchamp
@Brandon_Beaber @Wagner_Nephro @chicago_ellie The risk is probably less than you think - renal patients shouldn't be denied the most appropriate imaging where benefits outweigh risks https://t.co/814PFTuxzL
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
@anwarstanley @NephJC @askrenal Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis ca. 2019 #VisualAbstract by @VickiSandys
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
This meta drives the change https://t.co/b2Mce5S2rG
NSF: very interesting work done on Group II GBCA available here https://t.co/76PgPtnHb8 9/18 https://t.co/dM9FlavtxO
The Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease is very low as the is likely less than 0.07%. https://t.co/GBxXv81vaA For more info on gadolinium safety in CKD and ESRD, https://t.co/Y1bUmvwcf3
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
RT @bmactweet: Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group I…
Thanks @hswapnil and @NickSchiedaMD for pointing out this important practice changing research. The risk of NSF from group II GBCA administration in stage 4 or 5 CKD is likely less than 0.07%. Diagnostic harms of witholding GBCA may be higher in majority o
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
RT @NickSchiedaMD: ❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologis…
❓ How do we consent patients with #KidneyDisease for Gadolinium #MRI? 🟢 We don't https://t.co/TXZqWnr1wN @CARadiologists @hswapnil ❓ What is the risk of developing #NSF in at-risk patients? 🟢 Upper bound 95% CI = 0.07% https://t.co/4kG1XbuUx6 @JAMA_cu
RT @AJKDonline: Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change https://t.co/OmcMismvhh (FREE) #gadolinium #CKD Commentary by @Abualfaa on @JAMAInternalMed article ⬇️ https://t.co/Qzp97eJPP7
RT @AJKDonline: Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change https://t.co/7sK10rRkJQ (FREE) #gadoli…
RT @AJKDonline: Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change https://t.co/7sK10rRkJQ (FREE) #gadoli…
RT @PWoywodt: and so NSF takes its somewhat more senior colleague contrast nephropathy by the hand and both disappear into the sunset, join…
RT @AJKDonline: Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change https://t.co/7sK10rRkJQ (FREE) #gadoli…
and so NSF takes its somewhat more senior colleague contrast nephropathy by the hand and both disappear into the sunset, joining the club of diseases where the number of authors writing about them may exceed the number of cases...
Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change https://t.co/7sK10rRkJQ (FREE) #gadolinium #CKD Commentary by @Abualfaa on @JAMAInternalMed article ⬇️
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II GBCA quite low less then 0.07 percent. Dont have to think twice during rounds to prescribe them i guess https://t.co/8ofO2LJAti
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A ... - PubMed - NCBI https://t.co/YvWKc0WFG3
RT @DornbosIII_MD: Risk of 0% is pretty low ... contrast for everyone!
RT @1000yrscandy: Stage 4, 5のCKD患者へのGroup2 Gd造影剤投与によるNSFのリスクに関するmeta-analysis。発症リスクは0.07%以下でヨード系造影剤によるアナフィラキシー程度。 必要時に造影を避けることによる診断への害がNSFの…
@Dev_Sanghavi Agreed! Same goes for gad-based contrast on CKD patients. https://t.co/0BmGkNx4hB